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Abstract
Mutations in PARK7/DJ-1 gene are associated to autosomal recessive early onset forms of Parkinson’s disease (PD). Although
large gene deletions have been linked to a loss-of-function phenotype, the pathogenic mechanism of missense mutations is
less clear. The L166P mutation causes misfolding of DJ-1 protein and its degradation. L166P protein may also accumulate
into insoluble cytoplasmic aggregates with a mechanism facilitated by the E3 ligase TNF receptor associated factor 6
(TRAF6). Upon proteasome impairment L166P activates the JNK/p38 MAPK apoptotic pathway by its interaction with TRAF
and TNF Receptor Associated Protein (TTRAP). When proteasome activity is blocked in the presence of wild-type DJ-1,
TTRAP forms aggregates that are localized to the cytoplasm or associated to nucleolar cavities, where it is required for a
correct rRNA biogenesis. In this study we show that in post-mortem brains of sporadic PD patients TTRAP is associated to
the nucleolus and to Lewy Bodies, cytoplasmic aggregates considered the hallmark of the disease. In SH-SY5Y
neuroblastoma cells, misfolded mutant DJ-1 L166P alters rRNA biogenesis inhibiting TTRAP localization to the nucleolus and
enhancing its recruitment into cytoplasmic aggregates with a mechanism that depends in part on TRAF6 activity. This work
suggests that TTRAP plays a role in the molecular mechanisms of both sporadic and familial PD. Furthermore, it unveils the
existence of an interplay between cytoplasmic and nucleolar aggregates that impacts rRNA biogenesis and involves TRAF6.
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Introduction
The accumulation of misfolded proteins is a common feature to
a wide range of neurodegenerative diseases [1]. A neuropatho-
logical hallmark of Parkinson’s disease (PD) is the presence of
proteinaceous aggregates, known as Lewy Bodies (LBs), in the
cytoplasm of dopaminergic (DA) neurons of the Substantia Nigra,
the major target of neurodegeneration. In Huntington’s disease
(HD), N-terminal fragments of mutant huntingtin (N-HTT) form
intracellular aggregates in the brain [2].
Several evidences implicate malfunction of the ubiquitin-
proteasome system (UPS) in both idiopatic and familial PD [3].
Key UPS elements are altered in PD post-mortem brains [4],
while synthetic proteasome inhibitors preferentially affect cate-
cholaminergic neurons in vitro and in vivo leading to cell death [5,6].
DJ-1 is a ubiquitously expressed protein that is mutated in
autosomal recessive early onset forms of PD (PARK7) [7]. DJ-1 is
an anti-oxidant protein [8] involved in mitochondrial integrity [9],
autophagy [10] and hypoxia [11,12]. Together with phenotypes
due to large gene deletions, the exact pathogenic mechanism of
PD-causing missense mutations remains unclear. In the most
studied case, L166P disrupts DJ-1 protein activity and dimer
formation, resulting in a misfolded protein that undergoes
degradation [13]. However, mutant DJ-1 may also accumulate
into insoluble cytoplasmic aggregates [14,15] and acquire a gain-
of-function property that may co-exist with its loss of physiological
activity, as previously found for mutant HTT in HD [16] and
superoxide dismutase 1 (SOD1) missense mutations in amyotro-
phic lateral sclerosis (ALS) [17].
The formation of L166P-containing aggregates is facilitated by
atypical ubiquitination carried out by the TNF associated protein
6 (TRAF6) [15], a component of LBs in PD post-mortem brains.
Interestingly, TRAF6 activity also triggers aggregate formation of
mutant HTT suggesting a broader role of this E3 ligase in
neurodegenerative diseases [18].
TRAF and TNF Receptor Associated Protein (TTRAP) is a 59-
tyrosyl DNA phosphodiesterase that repairs topoisomerase-2-
induced DNA breaks [19]. In physiological conditions in neurons
TTRAP is a nuclear protein associated to PML Nuclear Bodies
(PML-NBs) [20]. It was originally described as involved in signal
transduction for its interaction with TNF receptors (TNFR) family
members and TNFR-associated factors (TRAFs), including
TRAF6 [21], as well as in transcriptional regulation for its
binding to ETS-related proteins [22]. TTRAP has been linked to
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35051PD for its ability to specifically interact with L166P DJ-1. When
UPS activity is inhibited, TTRAP mediates L166P toxicity via
JNK/p38 MAPK pathways providing the molecular basis for
L166P gain-of-function properties [23]. Interestingly, TTRAP
forms aggregates both in the cytoplasm and in nucleolar cavities, a
region of the nucleolus devoid of ribosomal markers [24]. Under
these conditions, TTRAP is neuroprotective and required for a
correct rRNA biogenesis [20].
The structure and function of the nucleolus have been recently
found altered in PD and essential to the survival of DA neurons in
vivo [25,26].
In this paper we show that in PD post-mortem brains TTRAP is
associated to LBs in the cytoplasm or accumulated in the nucleolus
in a portion of surviving DA neurons. In a cellular model of
familial PD linked to mutant DJ-1 L166P, accumulation of
misfolded proteins impairs rRNA biogenesis in vitro by inhibiting
TTRAP localization into nucleolar cavities. This is concomitant
with an increase in the number and size of cytoplasmic aggregates
containing both L166P and TTRAP. This phenotype depends, at
least in part, on TRAF6 E3 ligase activity.
Materials and Methods
Human post-mortem brains
Brain samples were obtained from the brain bank at the
Institute of Neuropathology, Bellvitge Hospital (University of
Barcelona, Spain). Samples were dissected at autopsy with the
informed consent of patients or their relatives and the institutional
approval of the Ethics Committee of the University of Barcelona.
Brains were obtained from Caucasian, pathologically confirmed
PD cases and age-matched controls [27]. Briefly, all cases of PD
had suffered from classical PD, none of them had cognitive
impairment and their neuropathological characterization was
made according to established criteria. Control healthy subjects
showed absence of neurological symptoms and of metabolic and
vascular diseases, and the neuropathological study disclosed no
abnormalities, including lack of Alzheimer disease and related
pathology. The time between death and tissue preparation was in
the range of 3 to 5 hours. The ventral midbrain region was
sectioned horizontally. The dark pigmented zones of the
Substantia Nigra were readily apparent from all surrounding
structures and were then isolated from the ventral midbrain. For
histological analysis, samples were cryoprotected with 30% sucrose
in 4% formaldehyde, frozen in dry ice and stored at 280uC until
use.
Immunohistochemistry
Immunohistochemistry was performed on three controls and six
PD human post-mortem brains. Only Substantia Nigra was
dissected and analyzed. Tissue processing and histology were
performed as previously described [15]. The following primary
antibodies were used: anti-TTRAP (1:50) [23] and anti-alpha-
synuclein (1:100, Cell Signaling Technology). Nuclei were
visualized with DAPI. DA neurons in the Substantia Nigra were
identified by neuromelanin staining with transmitted light.
Cell culture and transfections
Human neuroblastoma SH-SY5Y cells (ATCC) were maintained
in culture as suggested by the vendor. SH-SY5Y cells stably
transfected with pCDNA3-FLAG-DJ-1 wt and L166P or empty
vector control and with pSuperior-siDJ-1 or pSuperior-Scramble
were previously described [11,23]. All stably transfected SH-SY5Y
cells were kept in culture with neomycin selection. Proteasome
inhibition was performed for 16 hours with 5 mM MG132 (z-Leu-
Leu-al) (Sigma Aldrich). DJ-1 silencing was obtained by adding
2.5 mg/ml of Doxycicline Hyclate (Sigma Aldrich) every 48 hours
for a total of 10 days. GFP-TRAF6 (wt and DN) and N-HTT-GFP
Gln
21 and Gln
150 were previously described [15,18]. Transfections
were performed with Lipofectamine reagent (Invitrogen).
For silencing endogenous TRAF6 specific oligonucleotides
(Sigma Aldrich, EHU147511) were transiently transfected with
Oligofectamine (Invitrogen). Immunofluorescence and western
blot experiments were performed 72 hours after transfection.
Immunofluorescence
For immunofluorescence experiments, cells were fixed in 4%
paraformaldehyde directly added to culture medium for 10 min-
utes, then washed in PBS two times, treated with 0.1 M glycine for
4 minutes in PBS and permeabilized with 0,1% Triton X-100 in
PBS for another 4 minutes. After washing with PBS and blocking
with 0.2% BSA, 1% NGS, 0,1% Triton X-100 in PBS (blocking
solution), cells were incubated with the indicated antibodies
diluted in blocking solution for 90 minutes at room temperature.
To detect insoluble TTRAP, immunocytochemistry was per-
formed as described earlier [23].
We used anti-FLAG (1:1000, Sigma Aldrich), anti-TTRAP
(1:100), anti-NPM (1:100, Invitrogen), anti-Nucleolin (1:100,
Invitrogen), anti-PML (PG-M3) (1:100, Santa Cruz Biotechnolo-
gy), anti-p53 (DO1, Santa Cruz Biotechnology). For detection,
cells were incubated with Alexa Fluor-488 or -594 (Molecular
Probes, Invitrogen) labeled anti-mouse or anti-rabbit secondary
antibodies. For nuclear staining, cells were incubated with DAPI
(1 mg/ml) for 5 minutes. Triple immunofluorescence was per-
formed using Zenon technology: anti-NPM antibody was labeled
with Zenon Alexa Fluor 405 Mouse IgG(1) labeling reagent
(Invitrogen), according to manufacturer’s instructions. Cells were
washed and mounted with Vectashield mounting medium
(Vector). All images were collected using a confocal laser scanning
microscopy LEICA TCS SP2. The analysis of aggregates was
performed on high-resolution images using ImageJ software. At
least 100 cells from two independent experiments were counted
and scored for percentage of cells with aggregates and average
aggregate size.
RNA isolation, reverse transcription and qPCR
Total RNA was isolated using the TRIZOL reagent (Invitrogen)
following the manufacturer’s instructions. Single strand cDNA was
obtained from 1 mg of purified RNA using the iSCRIPT
TM cDNA
Synthesis Kit (Bio-Rad) according to manufacturer’s instructions.
Quantitative real time PCR (qPCR) was performed using SYBR-
Green PCR Master Mix (Applied Biosystem) and an iCycler IQ
Real time PCR System (Bio-Rad). Primers for rRNA biogenesis
A0, 1 and 4 [20], and for housekeeping genes beta-actin and
GAPDH [15] were previously described.
32P-orthophosphate in vivo labeling and RNA analysis
Metabolic labeling and analysis of rRNA was carried out as
previously described [20]. Briefly, mutant DJ-1 L166P and empty
control cells were treated with 5 mM MG132 for 16 h or left
untreated. Drug was maintained in the medium during the whole
time of the procedure. Cells were incubated with phosphate-free
medium supplemented with 10% dialyzed FBS (labeling medium)
for 1 h prior to labeling with
32P-orthophosphate (15 mCi/ml) in
labeling medium for 1 h (pulse). Medium was then replaced with
complete medium for 3 h (chase). Total RNA was extracted using
TRIZOL reagent (Invitrogen) and 1 mg of purified RNA was
separated on 1% agarose-formaldehyde gel. After electrophoresis,
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were dried. rRNA species were detected by autoradiography.
Proliferation and viability assays
Cell proliferation was measured by flow-cytometry (FACS)
upon propidium iodide staining. Briefly, SH-SY5Y cells stably
transfected with L166P and control cells were either left untreated
or treated with 5 mM MG132 for 16 hours. After treatment, cells
were collected, fixed with ice-cold 70% ethanol, treated with
RNase A (0.2 mg/ml), and stained with propidium iodide
(0.04 mg/ml). Samples were analyzed on a flow cytometer
(FacsCalibur, BD). FACS data were processed using FlowJo
software, and cell cycle profiles were determined using the Watson
pragmatic model (Tree Star).
Cell viability was measured using WST-1 reagent (Roche),
following manufacturer’s instructions and reading absorbance at
440 nm using a standard spectrophotometer. Percentage of live
cells after treatment with 5 mM MG132 for 16 hours was
calculated relative to DMSO-treated cells (set as 100% for each
cell line).
Cell fractionation and Western blot analysis
SH-SY5Y stable cells were lysed in a buffer containing 150 mM
NaCl, 50 mM Tris pH 7.5 and 0.2% TRITON X-100,
supplemented with protease inhibitor cocktail (Roche). Lysates
were centrifuged at 20 000 g for 30 min at 4uC and separated into
Triton X-100 soluble (supernatant) and insoluble (pellet) fractions.
Insoluble pellets were resuspended in boiling sample buffer,
sonicated and used for western blot analysis. The following
antibodies were used: anti-FLAG 1:2000 (Sigma), anti-TTRAP
1:1000, anti-TRAF6 (Santa Cruz), anti-beta-actin 1:5000 (Sigma).
For detection, anti-mouse-HRP or anti-rabbit-HRP (Dako) in
combination with ECL (GE Healthcare) were used.
Statistical analysis
All experiments were repeated in triplicate or more. For stably
transfected cells, at least two independent clones were used for
each cell line in all experiments. Data represent the mean with
standard deviation. When necessary, each group was compared
individually with reference control group using Student’s t-Test
(Microsoft Excel software).
Results
TTRAP is present in cytoplasmic LBs and in the nucleolus
of surviving dopaminergic neurons of PD post-mortem
brains
To study TTRAP localization in sporadic PD, we performed
immunohistochemical analysis in human post-mortem brains. A
total of six PD patients and three controls were examined
(Figure 1A). In normal conditions, TTRAP is expressed mainly in
the nucleus of DA neurons, identified for the presence of
neuromelanin. A weaker cytoplasmic staining is observed. Low
levels of TTRAP expression can also be found in non-DA neurons.
No staining was detected when control rabbit immunoglobulins
were used (data not shown). In human brain sections of sporadic
PD cases TTRAP expression was heterogeneous throughout
mesencephalic cells identifying at least four phenotypes. While a
small quantity of cells (15–20%) presented a nuclear distribution as
in controls, in the majority of DA neurons (80%) TTRAP was
exclusively relocalized to the cytoplasm, almost completely
emptying the nucleus. In about 1–20% of the cells, TTRAP
accumulated in large cytoplasmic aggregates. Double immunohis-
tochemical analysis using anti-alpha-synuclein antibody demon-
strated that these are bona fide LBs (Figure 1B). The patient-to-
patient variability, in conjunction with an uneven distribution of
aggregates in the Substantia Nigra, reflected the heterogeneous
distribution of LBs in post-mortem brains. In addition, in 1–2% of
surviving DA neurons, TTRAP diffuse cytoplasmic localization
was concomitant with the presence of TTRAP in the nucleolus, as
shown by lack of DAPI staining.
Altogether these data show that TTRAP is present in
cytoplasmic LBs as well as in the nucleolus in surviving
dopaminergic neurons of sporadic PD brains.
L166P mutant DJ-1 inhibits TTRAP localization in
nucleolar cavities
When SH-SY5Y neuroblastoma cells are treated with protea-
some inhibitors in vitro, TTRAP forms aggresome-like structures in
the cytoplasm and in the nucleolus where it participates in rRNA
biogenesis [20,23]. In these conditions it binds L166P, the protein
product of the most studied missense DJ-1 mutation in familial
PD. To test whether L166P binding might have an effect on
TTRAP localization, SH-SY5Y cells stably expressing FLAG-
tagged wt DJ-1 or PD-associated L166P were treated with
MG132. When nucleoli were visualized with the marker
Nucleophosmin (NPM), TTRAP was detected in the nucleolus
of about 60% of control cells upon proteasome block (Figure 2A,
2B) [20]. This localization was also observed when more specific
inhibitors of proteasome activity were used like epoxomicin and
lactacystin (Figure S1). No staining was observed in cells with
knock-down TTRAP expression (Figure S1). While overexpression
of wt DJ-1 had no effect on TTRAP nucleolar localization, the
presence of misfolded L166P mutant almost completely inhibited
TTRAP recruitment to the nucleolus (Figure 2A, 2B and figure
S2). No differences in TTRAP localization were observed in
untreated conditions, thus indicating that overexpression of wt or
mutant DJ-1 per se does not alter TTRAP subcellular distribution
(Figure 2B and Figure S2). Since L166P DJ-1 is expressed at lower
levels than wt protein and is generally associated to a loss-of-
function phenotype, we asked whether silencing DJ-1 expression in
SH-SY5Y cells could recapitulate the phenotype observed in
L166P expressing cells. We performed similar immuno-fluores-
cence experiments in SH-SY5Y cells with inducible loss of DJ-1
expression [11] by using two independent siDJ-1 (A, B) and
scramble (a, b) clones. The lack of DJ-1 protein did not affect
TTRAP localization, neither in untreated or MG132-treated cells
(Figure 2C, 2D, 2E and Figure S3).
To evaluate whether TTRAP exclusion from the nucleolus was
a phenotype common to other misfolded proteins involved in
neurodegenerative diseases, we studied TTRAP localization in a
cellular model of Huntington’s disease. SH-SY5Y cells were
transfected with huntingtin amino-terminal fragment (residues 1–
171) fused to green fluorescent protein (N-HTT-GFP) with either
a physiological (Gln
21) or a pathological (Gln
150) polyglutamine
(polyQ) stretch. N-HTT aggregates triggered by polyQ expansion
inhibited TTRAP nucleolar localization upon proteasome impair-
ment (Figure 2F, 2G), while no effects were observed when wt
Gln
21 N-HTT was used.
These data indicate that misfolding-causing mutations in
neurodegenerative diseases impact TTRAP nucleolar localization
upon proteasome inhibition.
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35051Figure 1. TTRAP is present in cytoplasmic Lewy bodies and in the nucleolus in surviving dopaminergic neurons in PD post-mortem
brains. (A) TTRAP localization in normal and PD dopaminergic neurons. Cryo-sections of post-mortem brain tissues were taken from Substantia Nigra
of healthy individuals and PD patients, as indicated. Immunohistochemistry was performed with anti-TTRAP antibody (green). Nuclei were stained
with DAPI (blue). Dopaminergic neurons were identified by neuromelanin (black) in transmitted light (TL). Overlays of fluorescence (merge) and
fluorescence with TL (TL merge) are shown. Panels are representative images showing TTRAP nuclear, cytoplasmic diffused, cytoplasmic aggregated
and nucleolar localization. The percentage of dopaminergic neurons with nuclear, cytoplasmic or nucleolar TTRAP staining is indicated on the right.
Bars, 15 mM. (B) TTRAP-containing cytoplasmic aggregates are Lewy bodies. Immunohistochemistry of Substantia Nigra from PD brains was
performed with anti-TTRAP (green) and anti-alpha-synuclein (red) antibodies. Images at low (16) and high (106) magnification are shown.
doi:10.1371/journal.pone.0035051.g001
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35051Figure 2. Mutant DJ-1 L166P inhibits TTRAP nucleolar localization after proteasome inhibition. (A) TTRAP nucleolar localization is
inhibited in L166P expressing cells. SH-SY5Y cells stably transfected with empty vector (c), FLAG-DJ-1 wt (W) or L166P (L) were treated with 5 mM MG132
for16 h.Triple immunofluorescencewasperformedwith anti-NPM(blue), anti-TTRAP(green)andanti-FLAG(red)antibodies. Imagesarerepresentatives
of three independent experiments. Data have been confirmed on two independent clones for each cell line. Bars, 10 mm. (B) Quantification of TTRAP
nucleolarlocalization.CellsasinA.Atleast200cellsfromtwoindependentexperimentswerecountedandscoredforTTRAPinthenucleolus (*,p,0.05).
(C) Localization of TTRAP is unaffected in cells depleted of endogenous DJ-1. SH-SY5Y cells stably expressing an inducible short-hairpin RNA targeting
DJ-1(siDJ-1,clonesA andB) or a scramble shRNAcontrol (scramble, clones a andb)weretreated with doxycyclinefor10days toinducesilencingofDJ-1
expression. Then cells were treated with 5 mM MG132 for 16 h. Immunofluorescence was performed with anti-TTRAP (green) and anti-NCL (red)
antibodies. Nuclei were visualized with DAPI (blue). Images are representatives of two independent experiments. Bars, 10 mm. (D) Quantification of
TTRAP nucleolar localization in siDJ-1 cells. Data were collected as in B. (NS, not-significant). (E) DJ-1 is efficiently depleted in siDJ-1 cells. Total protein
lysates were prepared from cells as in C. Levels of endogenous DJ-1 were measured by western blot with anti-DJ-1 antibody. Beta-actin was detected as
loading control. (F) TTRAP nucleolar localization is altered by mutant huntingtin. SH-SY5Y cells were transfected with huntingtin N-terminal fragment
fused to GFP with WT (Gln
21, Q21) or mutated (Gln
150, Q150) polyglutamine expansion. Endogenous TTRAP was visualized by indirect
immunofluorescence (red). N-HTT was visible by GFP autofluorescence. Nuclei were visualized with DAPI (blue). Bars, 10 mm. (F) Quantification of
TTRAP nucleolar localization in N-HTT expressing cells. Data were collected as in B on GFP-positive cells (*, p,0.05; NS, not-significant).
doi:10.1371/journal.pone.0035051.g002
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inhibition
Since we have previously found that nucleolar TTRAP
regulates rRNA biogenesis in conditions of proteasome inhibition
[20], we analyzed the levels of precursor rRNA molecules (pre-
rRNA) and of rRNA processing intermediates in SH-SY5Y stable
cells for wt DJ-1, mutant L166P and empty vector as control. Cells
were treated with MG132 and rRNA biogenesis was measured by
qPCR with A0, 1 and 4 primers as previously described [28,29,30]
[20]. A scheme of rRNA processing events and positioning of
qPCR primers on processing intermediates is shown in figure 3A.
In untreated conditions, A0, 1 and 4 probes detected no changes
dependent on wt or mutant DJ-1 overexpression (Figure 3B).
Upon proteasome inhibition, the levels of pre-rRNA containing
A0 sites were significantly increased (p,0.05). This pattern was
maintained in cells expressing wt DJ-1. On the contrary,
concomitant with the disappearance of nucleolar TTRAP, in
L166P cells the quantity of A0 sites was strongly reduced (p,0.05).
Furthermore, the amount of rRNA processing intermediates,
measured by oligonucleotides targeting 1 and 4 cleavage sites,
dramatically increased in L166P cells compared to wt DJ-1 and
controls (Figure 3B). No detectable alterations in pre-rRNA levels
were observed in inducible si-DJ-1 cells (Figure S4). Importantly,
no gross alterations in the structure of nucleoli were induced by
overexpression of L166P as proved with NPM staining (Figure S5).
To further investigate ribosome biogenesis in mutant DJ-1 cells,
we measured nascent rRNA by pulse-chase labeling with
32P-
orthophosphate. Untreated cells were used as controls. Metabol-
ically labeled rRNA species were visualized by autoradiography
(Figure 3C, upper panel) and loading was verified with ethidium
bromide (Figure 3C, lower panel). No differences in rRNA
processing were detected in untreated conditions between control
and mutant DJ-1 cells, thus confirming qPCR data. While
proteasome inhibition caused a marked reduction of 28S and
18S mature forms in both cell lines, mutant DJ-1 L166P
expression caused an increase in pre-rRNA precursors (47S/45S)
and an accumulation of the 32S processing intermediate.
Altogether, these results suggest that misfolded DJ-1 expression
has an impact both on the initial events of transcription and on the
conversion of intermediate to mature forms (47S to 45S and 32S to
28S). This phenotype resembles the one observed in neuroblas-
toma cells lacking TTRAP expression [20]. Analysis of cell
proliferation in untreated and treated conditions could not detect
any difference between control and mutant cells (Figure S6). A
small, but significant, decrease in cell viability could be observed in
L166P cells exposed to MG132 as compared to control cells
(Figure S6).
L166P-mediated exclusion of TTRAP from nucleolar
cavities does not depend on PML
The presence of PML and the integrity of PML-NBs in
nucleolar cavities are fundamental for TTRAP to be recruited to
the nucleolus in response to proteasome inhibition [20].
Therefore, we asked whether L166P-mediated exclusion of
TTRAP from nucleolar cavities might depend on L166P action
on PML-NBs. SH-SY5Y cells expressing wt, L166P or an empty
vector were treated with MG132 and PML localization was
followed by immunofluorescence using NPM as nucleolar marker
(Figure 4A). The number of cells with nucleolar PML-NBs was
scored in duplicates in two independent clones for each cell line (at
least 100 cells per experiment) (Figure 4B). Total levels of PML
protein were measured by western blot analysis (Figure 4C, 4D).
We found that L166P, similarly to wt and control cells, did not
impact PML expression or PML-NBs accumulation in nucleolar
cavities. Therefore, L166P inhibition of TTRAP nucleolar
accumulation is independent from PML. To further support this
model, we also checked whether MG132-induced nucleolar
localization of p53, another marker of nucleolar cavities, was
altered by L166P. Similarly to PML staining, we couldn’t observe
any change in p53 localization induced by overexpression of
misfolded mutant DJ-1, or in controls (Figure 4E, 4F). No changes
in TTRAP, PML and p53 localization were observed in untreated
cells (Figure S7).
Altogether our data indicate that L166P overexpression does
not impact the overall structure of nucleolar cavities but
specifically alters nucleolar localization of L166P-binding protein
TTRAP.
L166P enhances TTRAP accumulation into insoluble
cytoplasmic aggresomes
As MG132 treatment accumulates TTRAP into cytoplasmic
insoluble aggresome-like structures [23], we analyzed TTRAP
localization in cells that express wt DJ-1 or L166P after
permeabilization with Triton X-100 before fixation. In all cell
lines analyzed, endogenous TTRAP formed aggresome-like
structures in the cytoplasm, as expected (Figure 5A), whereas no
aggresomes were visible in untreated conditions (data not shown).
Interestingly, overexpression of L166P increased the percentage of
cells with TTRAP-containing cytoplasmic aggregates and pro-
moted the formation of inclusions with an average larger size
(Figure 5A, 5B, 5C).
In about half of SH-SY5Y cells stably transfected with DJ-1 wt
or empty vector, TTRAP was also present in the insoluble fraction
of the nucleolus. As expected, TTRAP accumulation in insoluble
nucleolar granules was almost completely inhibited in presence of
L166P mutant (Figure 5A). Interestingly, L166P itself was present
in TTRAP-positive cytoplasmic aggregates (figure 5A), whereas no
DJ-1 aggregates were visible in wt overexpressing cells.
Since mutant L166P promotes TTRAP accumulation in
cytoplasmic aggregates upon MG132 treatment, we analyzed
TTRAP distribution into insoluble fractions by western blot
analysis, proving a more evident accumulation in L166P-
expressing cells (Figure 5D) [23].
Altogether, these data demonstrate that L166P depletes
TTRAP from nucleolar cavities and enhances its recruitment into
L166P-containing insoluble cytoplasmic aggregates.
TRAF6 E3 ligase activity contributes to L166P-mediated
exclusion of TTRAP from nucleolar cavities
Since TTRAP and L166P co-localize in cytoplasmic insoluble
inclusions, we hypothesized that factors that promote L166P
aggregation might control TTRAP distribution between the
cytoplasm and the nucleolus. In a previous work, we have shown
that atypical ubiquitination by the E3 ligase TRAF6 enhances
L166P aggregate formation [15]. Therefore, we tested whether
TRAF6 E3 ligase activity might contribute to L166P-induced
TTRAP mislocalization. To this purpose we took advantage of a
TRAF6 mutant deleted of the N-terminal E3 ligase RING domain
(TRAF6 DN), that acts as dominant negative [31]. We transfected
SH-SY5Y cells stably expressing L166P with TRAF6 DN or wt
fused to GFP (Figure 6A, 6B). Cells expressing wt DJ-1 or empty
vector were used as controls. TTRAP localization in nucleolar
cavities was scored only in those cells with equivalent expression of
transfected constructs. Overexpression of wt TRAF6 had no effect
on TTRAP exclusion from nucleolar cavities induced by L166P.
Instead, TTRAP nucleolar localization was restored in about 20%
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phenotype was only partially penetrant. Overexpression of
TRAF6 or TRAF6 DN in stable cells for wt DJ-1 or empty
vector had no effects on TTRAP localization (Figure 6B). No
differences in TTRAP localization were observed in untreated
condition (Figure S8), thus indicating that overexpression of wt or
mutant TRAF6 per se does not alter TTRAP subcellular
distribution.
To further support the role of TRAF6 in excluding TTRAP
from nucleolar cavities, endogenous TRAF6 was silenced in
L166P-expressing cells with specific siRNA oligonucleotides.
Scramble siRNA and wt DJ-1 cells were used as controls.
Figure 3. Processing of rRNA is altered in L166P overexpressing cells. (A) Schematic diagram showing pre-rRNA structure and processing
steps. Positioning of A0, 1 and 4 cleavage sites on rRNA processing intermediates is shown. ETS, external transcribed spacer; ITS, internal transcribed
spacer. (B) Analysis of steady-state levels of rRNA precursor and processing intermediates. SH-SY5Y cells stably expressing wt DJ-1 (W), L166P (L) and
empty vector (c) were treated with Bars, 5 mM MG132 for 16 h, or left untreated. Total RNA was extracted and levels of pre-rRNA and processing
intermediates were analyzed by qPCR with primers targeting A0 , 1 and 4 cleavage sites. Standard deviations are calculated on four replicas from two
independent experiments. *, p,0.05. (C) Analysis of rRNA processing by metabolic labeling. L166P (L) and control (c) cells were treated as in A. After
treatment, cells were pulse-labeled with
32P-orthophosphate for 1 h and chased with cold medium for 3 h. RNA was extracted and equal quantities
were separated on denaturing agarose gel. Nascent rRNA was visualized by autoradiography after gel drying (upper panel). rRNA processing
intermediates and mature forms are indicated on the right. Loading was verified with ethidium bromide staining (lower panel).
doi:10.1371/journal.pone.0035051.g003
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35051Knocking-down TRAF6 expression recapitulated the phenotype
observed with TRAF6-DN, with partial recovery of nucleolar
TTRAP localization (Figure 6C, 6D and 6E). In line with partial
rescue of TTRAP nucleolar localization, knockdown of TRAF6
could also partially recover rRNA biogenesis defects in mutant DJ-
1 cells exposed to proteasome inhibition, although not all
processing intermediates were affected to the same extent (Figure
S9); this observation is also compatible with a DJ-1/TTRAP
independent role of TRAF6 in regulating ribosome biogenesis in
response to proteotoxic stress.
In any case, our data indicate that TRAF6 E3 ligase activity
contributes to TTRAP partitioning between cytoplasmic and
nucleolar aggregates in the presence of misfolded mutant DJ-1.
Discussion
L166P presents a structural rearrangement that interferes with
dimer formation favoring oligomerization and protein instability
[13,32]. This led to the hypothesis that DJ-1 deletions and
missense mutations share a common phenotype based on a loss-of-
function model. However, increasing evidences indicate that
missense mutations like L166P may also present gain-of-function
properties. L166P has exerted dominant-negative effects on the
antioxidant wt DJ-1 activity [33]. Gene profiling experiments in
DJ-1 KO and in L166P-NIH3T3 cells [34] have shown that
L166P affects the expression of a larger number of genes with no
common genes between these two conditions. Furthermore, tau
Figure 4. Mutant DJ-1 L166P does not inhibit nucleolar localization of PML and p53 upon proteotoxic stress. (A) Nucleolar localization
of PML. SH-SY5Y cells stably expressing wt DJ-1 (W), L166P (L) or empty vector (c) were treated with 5 mM MG132 for 16 h. Endogenous TTRAP
(green), PML (red) and NPM (blue) localization was analyzed by triple immunofluorescence. Images are representatives of two separate experiments
performed on two independent clones for each cell line. (B) Quantification of PML nucleolar localization. Cells were treated as in A. 200 cells from two
independent experiments were counted and scored for PML in the nucleolus (*, p,0.05). (C) Mutant DJ-1 L166P does not affect levels of endogenous
PML. SH-SY5Y cells stably expressing wt DJ-1 (W), L166P (L) or empty vector (c) were treated with 5 mM MG132 for 16 h or left untreated, as indicated.
The expression of endogenous PML and overexpressed FLAG-DJ-1 were measured with anti-PML and anti-FLAG antibodies, respectively. Beta-actin
was detected as loading control. (D) Quantification of PML levels. Densitometric analysis of protein bands was performed on two independent
experiments. Relative expression of endogenous PML was normalized to beta-actin. Data are expressed as the percentage of untreated condition in
empty cells (c). (E) Nucleolar localization of p53. Cells were exactly as in A. Localization of endogenous p53 (green), NPM (blue) and FLAG-DJ-1 (red)
were analyzed by triple immunofluorescence. Bars, 10 mm. (F) Quantification of p53 nucleolar localization. Analysis was performed as in B (NS, non
significant).
doi:10.1371/journal.pone.0035051.g004
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35051promoter was directly upregulated by L166P, in conditions when
wt DJ-1 was acting as a repressor. In this context, we have
previously shown that upon proteasome impairment L166P
blocked the neuroprotective property of TTRAP to MG132
treatment inducing JNK and p38 MAPKs apoptotic pathways
[23].
Here we provide evidences for a novel pathogenic mechanism
of mutant DJ-1 mediated by the sequestration of TTRAP. Upon
proteasome inhibition, L166P triggers alterations of rRNA
biogenesis by selectively excluding TTRAP from nucleolar cavities
and sequestering it into cytoplasmic aggregates. Inhibition of
TTRAP nucleolar localization by accumulated misfolded proteins
is not restricted to mutant DJ-1, but can also be observed for
aggregates of mutant huntingtin.
rRNA biogenesis is a complex process that requires the
transcription of rDNA genes by polymerase I, nucleolytic
cleavages and chemical modification of precursor rRNAs and
ultimately leads to the assembly of mature ribosomes [35]. It is
subjected to rigorous quality control mechanisms [36,37] and
stressful events elicit homeostatic responses that involve the
majority of its steps [38,39]. We have previously found that
TTRAP regulates rRNA biogenesis under proteasome impair-
ment. TTRAP down-regulation leads to a decrease of pre-rRNA
and a concomitant increase of processing species thus suggesting it
might function at multiple steps [20]. Accumulation of processing
intermediates might be due to impaired cleavage or to reduced
degradation of cleaved fragments, while the effects on pre-rRNA
levels may unveil a role of TTRAP at rDNA loci or may be
secondary to changes in rRNA processing [40].
Here we show that misfolded mutant DJ-1 expression
recapitulates this phenotype affecting the initial events of
transcription and the conversion of intermediate to mature forms
(47S to 45S and 32S to 28S). While both qPCR and pulse-chase
labeling with
32P-orthophosphate indicate an increase in the
amount of rRNA processing intermediates, the quantity of A0 sites
was strongly reduced when measured with qPCR while seemed
increased in pulse-chase experiment. To reconcile these data we
hypothesize that PCR amplification of the 59 ETS region of rRNA
precursors may detect illegitimate small RNA species due to
abortive transcription initiation that are not visible by gel
electrophoresis.
Several human genetic diseases, collectively defined as riboso-
mopathies, are caused by mutations in genes involved rRNA
biogenesis and ribosome assembly [41]. Surprisingly, few studies
so far have analyzed the status of protein synthesis, ribosome
biogenesis and of the nucleolus in human post-mortem brains of
neurodegenerative diseases. Alteration of protein synthesis capa-
bility due to ribosome dysfunction has been shown to be an early
event in Alzheimer’s disease [42]. A nucleolar protein involved in
ribosome biogenesis was found induced in post-mortem brains of
Huntington’s disease patients [43]. Nucleolin was identified as an
interactor of the PD-associated proteins DJ-1 and alpha-synuclein
and its protein expression was found reduced in Substantia Nigra
of human PD brains [25]. More recently, genetic ablation of
rRNA transcription caused an alteration of the nucleolus
architecture and ultimately neurodegeneration both in hippocam-
pal and dopaminergic neurons [26,44].
An analysis of rRNA biogenesis in post-mortem brains of
familial PD cases and in animal models of the disease is thus
Figure 5. L166P enhances TTRAP accumulation into insoluble
cytoplasmic aggresomes. (A) Cytoplasmic localization of TTRAP. SH-
SY5Y cells stably expressing wt DJ-1 (W), L166P (L) or empty vector (c)
were treated with 5 mM MG132 for 16 h. Before fixation, cells were
permeabilized with Triton X-100 and double immunofluorescence was
performed with TTRAP (green) and anti-FLAG (red) antibodies. Nuclei
were visualized with DAPI. Confocal images from two independent
experiments were scored for percentage of cells with aggregates (B),
and aggregate average size (C). At least 50 cells per experimental
condition were counted (*, p,0.05). (D) Mutant DJ-1 L166P promotes
accumulation of TTRAP in insoluble fraction. Cells were as in A. After
treatment with MG132, cells were lysed, and Triton X-100 insoluble
fraction was prepared. Endogenous TTRAP was analyzed by western
blotting with anti-TTRAP antibody. Protein loading was controlled by
beta-actin.
doi:10.1371/journal.pone.0035051.g005
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35051needed. Interestingly, the association of TTRAP to the nucleolus
of DA cells in sporadic PD brains increases the list of changes in
the nucleolar composition in PD. Their functional effects remain
to be investigated.
Recently, nucleolar aggregates have been identified as a novel
form of nuclear stress bodies that occupy nucleolar cavities
[20,28]. They contain polyadenylated RNA, unconjugated
ubiquitin and several nucleoplasmic proteasome target proteins
[28]. Their formation was relieved by an excess of free cytoplasmic
ubiquitin and occurred with both wt and triple mutant ubiquitins
lacking K48, K29 and K63 lysines, proving that atypical
ubiquitination is involved. This led to the hypothesis that a
cross-talk between cytoplasmic and nucleolar aggregates regulates
the subcellular localization of atypically ubiquitinated misfolded
proteins.
The partitioning of TTRAP between nucleolar and cytoplasmic
aggregates is modulated by TRAF6. This E3 ligase binds both
TTRAP and mutant DJ-1 promoting atypical ubiquitination of
L166P and its accumulation in cytoplasmic aggregates [15]. When
TRAF6 ligase activity is lacking, L166P inclusions are smaller and
TTRAP is relieved to relocate, at least in part, into the nucleolus.
Other E3 ubiquitin ligases, such as parkin [45], have been
Figure 6. TRAF6 E3 ligase activity contributes to L166P-mediated exclusion of TTRAP from nucleolar cavities. (A) Expression of TRAF6
DN partially rescues TTRAP nucleolar localization in L166P cells. SH-SY5Y cells stably expressing mutant DJ-1 were transfected with GFP-tagged TRAF6
(wt or deleted of the N-terminus, DN), or with empty vector control, as indicated. After 24 h from transfection, cells were treated for 16 h with MG132.
TTRAP localization was followed by indirect immunofluorescence coupled with GFP autofluorescence. Bars, 10 mm. (B) Quantification of TTRAP
nucleolar localization. Cells were as in A. At least 100 transfected cells with comparable GFP levels from two independent experiments were counted
and scored for TTRAP in the nucleolus (*, p,0.05). (C) Knock-down endogenous TRAF6 expression partially rescues TTRAP nucleolar localization. SH-
SY5Y cells stably transfected with mutant DJ-1 L166Pwere transfected with siRNA oligonucleotides targeting endogenous TRAF6 (siTRAF6) or with a
scramble control siRNA (Scr). After 72 h from transfection, cells were treated for 16 h with MG132. Immunofluorescence was performed with anti-
TTRAP (green), anti-TRAF6 (red), anti-NPM (blue). Bars, 15 mm. (D) Quantification of TTRAP nucleolar localization. Cells were as in C. Analysis was
performed as in B on cells with reduced TRAF6 expression (*, p,0.05). (E) Total cell lysates were prepared from SH-SY5Y cells transfected as in C. Cells
were treated with MG132 for 16 h or left untreated. Expression of endogenous TRAF6 and TTRAP was measured with specific antibodies. Protein
loading was controlled by beta-actin. Molecular weight markers (MWM) are indicated for each gel (kDa). Images are representative of two
independent experiments.
doi:10.1371/journal.pone.0035051.g006
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35051demonstrated to act on mutant DJ-1, possibly accounting for
additional TRAF6-independent regulation. TRAF6, as other E3
ubiquitin ligases, is accumulated in LBs [15]. In this context, the
aberrant localization of TTRAP in LBs and in the nucleolus of
sporadic PD post-mortem brains may suggest the existence of this
regulatory pathway in vivo. On the other hand, the impact of
TTRAP sequestration and consequent alteration in rRNA
biogenesis in familial cases will ultimately depend on the level of
L166P protein, which remains unknown. In summary this work
demonstrates a novel role for misfolded mutant DJ-1 in the
homeostasis of rRNA biogenesis and suggests the existence of a
functional interplay between cytoplasmic and nucleolar aggregates
that mayregulatenucleolarfunctionsinneurodegenerativediseases.
Supporting Information
Figure S1 Quantitative analysis of TTRAP nucleolar
localization. (A) TTRAP localizes to the nucleolus upon
proteotoxic stress. SH-SY5Y cells were treated with increasing
concentration of Epoxomycin or Lactacystin, as indicated.
Untreated cells were used as controls. TTRAP was visualized
with indirect immunofluorescence with anti-TTRAP antibody
(green). Nuclei were visualized with DAPI (blue). Nucleolar
TTRAP was scored in DAPI-negative regions in .100 cells.
Representative images are shown for cells treated with 1 mM
Epoxomycin and 25 mM Lactacystin. (*, p,0.05). (B) TTRAP
staining is specific. SH-SY5Y cells stably expressing a short-hairpin
RNA targeting TTRAP (siTTRAP #1 and #2) or a scrambled
shRNA control (scramble #1 and #2) were treated for 16 h with
5 mM MG132. TTRAP (green) and nuclei (blue) were stained as in
A.
(TIF)
Figure S2 Altered TTRAP nucleolar localization in
L166P mutant cells upon treatment with MG132. SH-
SY5Y cells stably transfected with empty vector (c), FLAG-DJ-1 wt
(W) or L166P (L) were treated with 5 mM MG132 for 16 h or left
untreated. TTRAP localization was analyzed by immunofluores-
cence with anti-TTRAP (green) and anti-FLAG (red) antibodies.
Nuclei were visualized by DAPI staining (blue). Low magnification
images are shown. Nucleolar TTRAP is evident in DAPI-negative
regions of the nucleus (white arrows). Images are representatives of
three independent experiments from two independent clones for
each cell line.
(TIF)
Figure S3 Analysis of DJ-1 expression in siDJ-1 and
scramble SH-SY5Y cells. SH-SY5Y cells stably expressing a
doxycyclin-inducible short-hairpin targeting DJ-1 (siDJ-1, clones A
and B) or a scramble shRNA control (scramble, a and b) were
treated with doxycycline for 10 days. Endogenous DJ-1 expression
was analyzed by immunofluorescence with anti-DJ-1 antibody.
(TIF)
Figure S4 Depletion of DJ-1 does not alter transcription
and processing of ribosomal RNA. SH-SY5Y stably
expressing a doxycyclin-inducible shRNA targeting DJ-1 (siDJ-1,
clones A and B) or a scramble shRNA control (scramble, a and b)
were induced 10 days with doxyciclin and then treated with 5 mM
MG132 for 16 h, or left untreated. Total RNA was extracted and
levels of pre-rRNA and processing intermediates were analyzed by
qPCR. Amplicons are those described in figure 3. Standard
deviations are calculated from two independent experiments.
Differences between a, b, A and B are not statistically significant
(*, P,0.05. NS, not significant).
(TIF)
Figure S5 Analysis of the effects of wild-type and
mutant DJ-1 on nucleolar integrity. SH-SY5Y cells stably
expressing wt DJ-1 (W), L166P (L) or empty vector (c) were treated
with 5 mM MG132 for 16 h. Immunofluorescence was performed
with anti-NPM antibody and NPM nucleoplasmic staining was
measured with ImageJ software on a randomly selected area.
Background fluorescence was quantified from an area placed
outside the cells and was subtracted for each signal. At least 100
cells from two separate experiments were counted (NS, not
statistically significant). Representative zoomed images are shown
for each cell line.
(TIF)
Figure S6 Analysis of the effects of mutant DJ-1 L166P
on cell proliferation and viability. (A) Expression of L166P
does not affect the cell cycle. SH-SY5Y cells stably expressing the
L166P mutant and control cells were treated for 16 h with 5 mM
MG132, or DMSO as control. Cell proliferation was analyzed by
flow-cytometry (FACS) after propidium iodide (PI) staining.
Graphs show the overlay of representative FACS profiles for each
sample. (B) Quantification of the cell cycle distribution in control
and L166P cells treated as in A. Data are from three independent
experiments (error bars, standard deviation). (C) Expression of
L166P DJ-1 moderately sensitizes cells to death induced by
proteasome inhibition. Identical numbers of L166P and control
cells were seeded in 96-well plates. After 24 hours, cells were
treated with DMSO or 5 mM MG132 for additional 16 h. Cell
viability was measured by WST-1 assay. Data are normalized to
WST activity in untreated cells. Standard deviations are calculated
from four independent experiments (*, p,0.05).
(TIF)
Figure S7 Localization of PML and p53 is not affected
by the expression of DJ-1 L166P mutant in untreated
cells. (A) Localization of PML. SH-SY5Y cells stably expressing
FLAG-tagged DJ-1 wt (W), or mutant (L) or empty vector (c) were
stained by triple immunofluorescence with anti-TTRAP (green),
anti-PML (red) and anti-NPM (blue) antibodies. (B) Localization of
p53. Cells were stained by triple immunofluorescence with anti-
NPM (blue), anti-p53 (green) and anti-FLAG (red) antibodies.
Bars, 10 mm.
(TIF)
Figure S8 TRAF6 expression does not alter TTRAP
localization in untreated cells. SH-SY5Y stably expressing
L166P were transfected with GFP-TRAF6 (wt and DN), as
indicated. Cells were left untreated. TTRAP localization was
analyzed by immunofluorescence with anti-TTRAP (red) anti-
body. Bars, 10 mm.
(TIF)
Figure S9 Analysis of rRNA biogenesis in mutant DJ-1
L166P cells with knock-down of TRAF6 expression. SH-
SY5Y cells stably transfected with mutant DJ-1 L166P were
transfected with oligonucleotides targeting endogenous TRAF6
(siRNA TRAF6) or a scramble control sequence (siRNA
Scramble). After 72 h from transfection, cells were treated for
16 h with MG132 or DMSO as control. Total RNA was extracted
and levels of pre-rRNA and processing intermediates were
analyzed by qPCR with primers targeting A0, 1 and 4 cleavage
sites, as indicated. Efficiency of TRAF6 knock-down was
monitored with specific primers (TRAF6). Standard deviations
are calculated from four independent experiments (*, P,0.05).
(TIF)
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